2.16

3.57% -0.08

After Hours: 2.16

Lipocine Inc (LPCN)

Overview News Price History Financials Discussions Forecast Stock Split

Lipocine Inc stock is traded at $2.16, with a volume of 64,253. It is down -3.57% in the last 24 hours and up +3.35% over the past month. Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Previous Close:

$2.24

Open:

$2.13

24h Volume:

64,253

Relative Volume:

1.23

Market Cap:

$17.81M

Revenue:

$2.00M

Net Income/Loss:

$-11.43M

P/E Ratio:

-1.1037

EPS:

-1.957

Net Cash Flow:

$-10.05M

1W Performance:

-1.14%

1M Performance:

+3.35%

6M Performance:

-69.79%

1Y Performance:

-24.48%

1-Day Range:

$2.12

$2.22

1-Week Range:

$2.10

$2.25

52-Week Range:

$1.81

$12.37

Lipocine Inc Stock (LPCN) Company Profile

Name

Lipocine Inc

Sector

Healthcare (1068)

Industry

Biotechnology (597)

Phone

801 994 7383

Address

675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

LPCN's Discussions on Twitter

Compare LPCN vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LPCN Lipocine Inc	2.16	18.71M	2.00M	-11.43M	-10.05M	-1.957
VRTX Vertex Pharmaceuticals Inc	514.99	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.90	80.46B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	182.56	57.48B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	963.79	61.58B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	368.08	39.20B	5.76B	514.49M	1.10B	4.4813

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-06-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-24-21	Initiated	Cantor Fitzgerald	Overweight
Dec-10-20	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-12-18	Reiterated	H.C. Wainwright	Buy
Jan-11-18	Downgrade	Canaccord Genuity	Buy → Hold
Dec-08-17	Resumed	H.C. Wainwright	Buy
Oct-07-16	Initiated	H.C. Wainwright	Buy
Jul-22-15	Initiated	ROTH Capital	Buy
Jun-23-15	Initiated	Canaccord Genuity	Buy

View All

Lipocine Inc Stock (LPCN) Latest News

Sep 11, 2026

Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Australia

Sep 11, 2026

Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine

Sep 11, 2026

Lipocine Cuts ATM Sales Agent Fee to Up to 3.0% - minichart.com.sg

Sep 11, 2026

Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com India

Sep 11, 2026

Lipocine Updates Sales Agreement Fee Structure with A.G.P. - TipRanks

Sep 11, 2026

Lipocine (LPCN) sets sales agent commissions at up to 3% - Stock Titan

Sep 11, 2026

Sep 10, 2026

Form 8K Lipocine Inc For: 10 September By Investing.com - Investing.com South Africa

Sep 10, 2026

Lipocine to present at H.C. Wainwright conferen... - Pluang

Sep 10, 2026

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire

Sep 10, 2026

Lipocine (LPCN) Advances 3.06% to $2.35, Testing Key Resistance ZoneSeasonality Effect - vinanet.vn

Sep 02, 2026

Aug 26, 2026

Lipocine (LPCN) Jumps 5.35% to $2.27 as Buyers Target $2.38 ResistanceTRIN Signal - vinanet.vn

Aug 26, 2026

Aug 25, 2026

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight - Yahoo Finance

Aug 25, 2026

Aug 23, 2026

Lipocine (LPCN) Q2 2026 Results: The Bottom-Line Figure Beats Its Comparison for the Current Session; After Results: The Share Price Moves Only Slightly under the Current SnapshotGross Profit Margin - vinanet.vn

Aug 23, 2026

Aug 21, 2026

Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan

Aug 21, 2026

Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn

Aug 21, 2026

Aug 18, 2026

Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et

Aug 18, 2026

Aug 17, 2026